1. Home
  2. CVEO vs CHRS Comparison

CVEO vs CHRS Comparison

Compare CVEO & CHRS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Civeo Corporation (Canada)

CVEO

Civeo Corporation (Canada)

HOLD

Current Price

$34.23

Market Cap

297.0M

ML Signal

HOLD

Logo Coherus BioSciences Inc.

CHRS

Coherus BioSciences Inc.

HOLD

Current Price

$1.58

Market Cap

296.8M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
CVEO
CHRS
Founded
1977
2010
Country
United States
United States
Employees
N/A
N/A
Industry
Hotels/Resorts
Biotechnology: Biological Products (No Diagnostic Substances)
Sector
Consumer Discretionary
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
297.0M
296.8M
IPO Year
2013
2014

Fundamental Metrics

Financial Performance
Metric
CVEO
CHRS
Price
$34.23
$1.58
Analyst Decision
Strong Buy
Strong Buy
Analyst Count
1
4
Target Price
$37.00
$5.51
AVG Volume (30 Days)
68.1K
1.3M
Earning Date
05-01-2026
05-07-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
472.00
EPS
N/A
N/A
Revenue
N/A
N/A
Revenue This Year
$7.72
$73.08
Revenue Next Year
$5.61
$30.94
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$19.75
$0.72
52 Week High
$36.50
$2.62

Technical Indicators

Market Signals
Indicator
CVEO
CHRS
Relative Strength Index (RSI) 67.01 39.51
Support Level $21.32 $1.55
Resistance Level $34.80 $1.80
Average True Range (ATR) 1.76 0.11
MACD 0.25 -0.02
Stochastic Oscillator 64.27 1.83

Price Performance

Historical Comparison
CVEO
CHRS

About CVEO Civeo Corporation (Canada)

Civeo Corp provides hospitality services to the natural resources industry in Canada, Australia. The company provides a full suite of services for guests, including lodging, catering and food service, housekeeping and maintenance at accommodation facilities that the company or its customers own. The company provides services that support the day-to-day operations of these facilities, such as laundry, facility management and maintenance, water and wastewater treatments, power generation, communication systems, security and logistics. The company operates in active oil, metallurgical coal, liquefied natural gas and iron ore-producing regions. The company operates in three reportable business segments Canada, and Australia. It derives maximum revenue from Australia.

About CHRS Coherus BioSciences Inc.

Coherus Oncology Inc is a fully integrated commercial-stage inventive oncology company with an approved next-generation PD-1 inhibitor, LOQTORZI, and a pipeline that includes two mid-stage clinical candidates targeting liver, lung, head & neck, and other cancers. Its portfolio includes LOQTORZI which was developed for its ability to block PD-1 interactions with its ligands, PD-L1 and PD-L2, by binding to the FG loop on the PD-1 receptor. Company believe blocking PD-1 interactions with PD-L1 and PD-L2 can help to promote the immune systems.

Share on Social Networks: